Trial Profile
VECTIBIX PLUS OXALIPLATIN-BASED ADJUVANT TREATMENT OF RECTAL CANCER.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2012
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Rectal cancer
- Focus Adverse reactions
- Acronyms VECTOX
- 28 Mar 2012 Actual end date (20 Dec 2011) added as reported by European Clinical Trials Database.
- 28 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 14 Jun 2011 New trial record